Cargando…

The Effectiveness of an Oral Fixed-Dose Combination of Netupitant and Palonosetron (NEPA) in Patients With Multiple Risk Factors for Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Observational Indian Study

Background Female gender, young age, first chemotherapy cycle, and low alcohol intake have all been linked to an increased risk of nausea and vomiting from chemotherapy. We intended to see if netupitant and palonosetron (NEPA) could prevent chemotherapy-induced nausea and vomiting (CINV) in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vaswani, Bharat, Dattatreya, Palanki S, Barkate, Hanmant, Bhagat, Sagar B, Patil, Saiprasad, Jadhav, Amit Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573141/ https://www.ncbi.nlm.nih.gov/pubmed/36259011 http://dx.doi.org/10.7759/cureus.29094

Ejemplares similares

The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting
por: Vaswani, Bharat, et al.
Publicado: (2021)

Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India
por: Vaswani, Bharat, et al.
Publicado: (2020)

Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
por: Navari, Rudolph M
Publicado: (2014)

Management of Chemotherapy-Induced Nausea and Vomiting (CINV): A Short Review on the Role of Netupitant-Palonosetron (NEPA)
por: Lorusso, Vito, et al.
Publicado: (2020)

Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice
por: Aapro, Matti, et al.
Publicado: (2022)

Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV)
por: Baron-Hay, Sally, et al.
Publicado: (2019)

NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK
por: Cawston, Helene, et al.
Publicado: (2017)

Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic
por: Hesketh, Paul J., et al.
Publicado: (2017)

Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective
por: Nilsson, Jonas, et al.
Publicado: (2022)

Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
por: Shirley, Matt
Publicado: (2021)

The First Oral Fixed-Dose Combination of Netupitant and Palonosetron for the Treatment of Chemotherapy-Induced Nausea and Vomiting
por: Coyne, Joseph W.
Publicado: (2016)

Correction to: Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting
por: Shirley, Matt
Publicado: (2021)

Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective
por: Vaid, Ashok K., et al.
Publicado: (2020)

Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron
por: Lorusso, Vito
Publicado: (2016)

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
por: Gralla, R. J., et al.
Publicado: (2014)

Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin’s lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation
por: Di Renzo, Nicola, et al.
Publicado: (2021)

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
por: Aapro, M., et al.
Publicado: (2014)

Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis
por: Botteman, Marc, et al.
Publicado: (2019)

Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant–palonosetron combination
por: Janicki, Piotr K
Publicado: (2016)

NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
por: Aapro, Matti, et al.
Publicado: (2016)

Complementary Pharmacokinetic Profiles of Netupitant and Palonosetron Support the Rationale for Their Oral Fixed Combination for the Prevention of Chemotherapy‐Induced Nausea and Vomiting
por: Gilmore, James, et al.
Publicado: (2018)

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
por: Hesketh, P. J., et al.
Publicado: (2014)

Fixed combination of oral NEPA (netupitant‐palonosetron) for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double‐blind phase III studies
por: Schwartzberg, Lee, et al.
Publicado: (2019)

Evaluating the impact of chemotherapy-induced nausea and vomiting on daily functioning in patients receiving dexamethasone-sparing antiemetic regimens with NEPA (netupitant/palonosetron) in the cisplatin setting: results from a randomized phase 3 study
por: Celio, Luigi, et al.
Publicado: (2022)

A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)
por: Zhang, L, et al.
Publicado: (2018)

Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study
por: Chang, Jianhua, et al.
Publicado: (2020)

Safety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin’s lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience
por: Zilioli, Vittorio R, et al.
Publicado: (2020)

Management of postoperative nausea and vomiting: focus on palonosetron
por: Muchatuta, Neil A, et al.
Publicado: (2009)

Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus
por: Desai, Chirag, et al.
Publicado: (2022)

Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trial
por: Spinelli, Tulla, et al.
Publicado: (2014)

ExPert ConsEnsus on the management of Advanced clear-cell RenaL celL carcinoma: INDIAn Perspective (PEARL-INDIA)
por: Sahoo, Tarini Prasad, et al.
Publicado: (2023)

Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study
por: Caputo, Roberta, et al.
Publicado: (2020)

Use of single-inhaler triple therapy in the management of obstructive airway disease: Indian medical experts’ review
por: Dhar, Raja, et al.
Publicado: (2022)

ICS/Ultra LABA in the Treatment of Obstructive Airway Diseases: A Consensus of Indian Experts
por: Dhar, Raja, et al.
Publicado: (2022)

Comparison of palonosetron with combined palonosetron and midazolam for preventing postoperative nausea and vomiting after laparoscopic cholecystectomy
por: Choi, Eun Kyung, et al.
Publicado: (2021)

Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron
por: Bajetta, Emilio, et al.
Publicado: (2009)

Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy
por: Navari, Rudolph M
Publicado: (2009)

Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron
por: Zhou, Michelle, et al.
Publicado: (2015)

Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience
por: Loteta, Barbara, et al.
Publicado: (2021)

Drug–drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data
por: Natale, James J, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hqrggegttg8gbrf3pqqtaac1uj